The promising anti-tumor impact of Newcastle disease virus expressing IL-2 and P53 genes in many cancer cell lines in vitro

Abstract EN

Recombinant Newcastle disease virus (rNDV) has shown an anticancer effect in preclinical studies, but has never been tested in a lung cancer models.

In this study we explored the anticancer activity of genetically modified NDV expressing IL-2-P53 (rClone30–IL-2-P53) in lung cancer model.

We have cloned IL-2 and P53 genes and inserted them in the viral genome of New Castle Disease Virus to create a genetically modified rNDV- IL-2-P53 virus and tested the anti-tumor activity of the new virus in vitro on different types of cancer cell lines by MTT assay.

TheIL-2 and P53 gene were successfully cloned and inserted into the viral genome by using a Mlu I and Sfi I endonucleases, viral vector was constructed correctly and successfully; sequencing results also showed that the recombinant plasmid was successfully constructed resulting in the formation of rClone30 NDV expressing both IL2 and P53 gene.

In this study, P53 and IL-2 gene were successfully constructed into the NDV genome, by the use of reverse genetics technology, then successfully rescue of all recombinant rNDVclone30s and got high titer recombinant viruses.